CD22


Also found in: Wikipedia.

CD22

a type I transmembrane protein found in the cytoplasm of pre-B cells and on the surface of mature B cells that facilitates signal transduction; expressed in patients with hairy cell leukemias and in some with B-cell lymphomas.
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
GTB-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors thereby maximizing cancer cell recognition by binding to CD19+, CD22+ and CD19+/CD22+ cancer cells.
The compound was approved in 2017 and consists of a humanized monoclonal antibody against CD22 where inotuzumab is linked to ozogamicin, a highly cytotoxic agent from the class of calicheamicins.
This set of patent applications primarily involves an innovative, versatile and inducible transposon-based vector system composed of humanized CD19 and CD22 dual and bispecific CARs with a safety switch targeted by Rituximab.
Pursuant to the CRADA, Neurotrope will collaborate with the NCI's Center for Cancer Research, Pediatric Oncology Branch (POB) to develop a Phase I clinical trial testing the safety and toxicity of Bryostatin-1 in children and young adults with CD22 + leukemia and B-cell lymphoma.
Peripheral blood flow cytometric immunophenotyping revealed a 40% population of aberrant B-lymphoblasts, that were CD45 (-), CD10 (+), CD22 (+), CD20 variably (+), CD19 (+), HLA-DR variably (+), CD34 partial (+), CD56 partial (+), Tdt (+), and negative for the remaining lymphoid and myeloid markers tested, including CD14, CD5, CD7, CD33, CD13, CD3, CD4, CD8, CD117, CD16, and MPO (Figure 2).
Commonly expressed CD markers on T-lymphocytes include CD2, CD3, CD5, CD7 while CD19, CD20, CD22, CD79a are common markers expressed on B cell.
CD22 is a B-lymphocyte restricted transmembrane protein with a higher receptor density in HCL cells relative to normal B cells, making it an attractive therapeutic target for the treatment of this cancer.
B cells express other ITIM-containing membrane molecules such as CD22, Siglec-G/Siglec-10, PIR-B, and PECAM-1.
They have a mature B-cell phenotype and typically express single or multiple immunoglobulin light chains and pan-B-cell antigens, such as CD19, CD20, CD22, and CD79b, but not CD21 (late B-cell marker).
Bonifant et al., "Twopronged cell therapy for B-cell malignancies: engineering NK cells to target CD22 and redirect bystander T cells to CD19," Blood, vol.
The monoclonal antibodies (MoAb) used for diagnosis of AL were: for B-lineage: CD19, CD22, CD20, CD10, for T-lineage: CD2, CD3, CD5, CD7, CD4, CD8, for myelo-monocytic lineage: CD13, CD33, CD11c, CD64, CD14, other cells surface markers: CD34, CD117, HLA-DR and intracellular MoAb: CD79a, CD3 and MPO.